Impact of Morning Light Therapy in IBD

Inclusion Criteria:

• Patients with ulcerative colitis and signs of inflammation (Fecal calprotectin >150mcg/g and/or CRP >5)

Exclusion Criteria:

• Known pregnancy or currently lactating women

• Current malignancy or active treatment for previously diagnosed malignancy. Patientswith squamous and basal cell cancer of the skin are eligible for the study.

• Serious co-morbidity including: Immunodeficiency, recent myocardial infarction orstroke, history of renal or hepatic failure, infection such as abscess,opportunistic infection, or sepsis.

• Patients with pacemaker or defibrillators

• The use of medications known to affect autonomic nervous system function, includingbut not limited to beta-blockers and benzodiazepines.

• Comprehension of the English language not adequate to understand the questionnaires

• Recent changes in IBD directed therapies within the last 3 months

• Regular use of antidiarrheal agents.

• Regular use of medications that have been shown to impair sleep (e.g. steroids,stimulants). If willing (and medically appropriate) to washout for 4 weeks,participant can be then enrolled in the study

• Regular use of sleep medications including but not limited to: benzodiazepinehypnotics, non-benzodiazepine hypnotics, antipsychotics, and melatonin. If willing (and medically appropriate) to washout for 4 weeks, participant can be then enrolledin the study

• Patients with prior colectomy or total proctocolectomy

• History of any surgery within 3 months

• Untreated Obstructive Sleep Apnea

• Blindness or severely impaired, uncorrected vision

• Employment which includes nocturnal shift work

• Traveling multiple time zones within the study time frame

• Any marijuana or illicit drugs use within one month of enrollment or ongoing basis